(NASDAQ: GILD) Gilead Sciences's forecast annual revenue growth rate of 3.37% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.68%.
Gilead Sciences's revenue in 2025 is $29,087,000,000.On average, 30 Wall Street analysts forecast GILD's revenue for 2025 to be $36,763,818,588,736, with the lowest GILD revenue forecast at $34,771,287,114,198, and the highest GILD revenue forecast at $38,714,166,956,092. On average, 30 Wall Street analysts forecast GILD's revenue for 2026 to be $37,974,721,900,784, with the lowest GILD revenue forecast at $34,923,890,707,827, and the highest GILD revenue forecast at $40,709,179,789,876.
In 2027, GILD is forecast to generate $40,040,453,473,079 in revenue, with the lowest revenue forecast at $37,273,737,913,789 and the highest revenue forecast at $42,400,226,116,025.